United States Triple-Negative Breast Cancer Treatment Market Report 2017

December 2017 | 97 pages | ID: UBFA039103FEN
QYResearch

Abstracts

In this report, the United States Triple-Negative Breast Cancer Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Triple-Negative Breast Cancer Treatment in these regions, from 2012 to 2022 (forecast).

United States Triple-Negative Breast Cancer Treatment market competition by top manufacturers/players, with Triple-Negative Breast Cancer Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Celgene
• Roche
• Immunomedics GmbH
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Eisai Co., Ltd

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Alkylating Agents
• Plant Products
• Microorganism Products
• Antimetabolites
• Microtubule Stablizing Agents

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital Pharmacies
• Retail Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Triple-Negative Breast Cancer Treatment Market Report 2017

1 TRIPLE-NEGATIVE BREAST CANCER TREATMENT OVERVIEW

1.1 Product Overview and Scope of Triple-Negative Breast Cancer Treatment
1.2 Classification of Triple-Negative Breast Cancer Treatment by Product Category
  1.2.1 United States Triple-Negative Breast Cancer Treatment Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Triple-Negative Breast Cancer Treatment Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Alkylating Agents
  1.2.4 Plant Products
  1.2.5 Microorganism Products
  1.2.6 Antimetabolites
  1.2.7 Microtubule Stablizing Agents
1.3 United States Triple-Negative Breast Cancer Treatment Market by Application/End Users
  1.3.1 United States Triple-Negative Breast Cancer Treatment Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital Pharmacies
  1.3.3 Retail Pharmacies
1.4 United States Triple-Negative Breast Cancer Treatment Market by Region
  1.4.1 United States Triple-Negative Breast Cancer Treatment Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Triple-Negative Breast Cancer Treatment Status and Prospect (2012-2022)
  1.4.3 Southwest Triple-Negative Breast Cancer Treatment Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Triple-Negative Breast Cancer Treatment Status and Prospect (2012-2022)
  1.4.5 New England Triple-Negative Breast Cancer Treatment Status and Prospect (2012-2022)
  1.4.6 The South Triple-Negative Breast Cancer Treatment Status and Prospect (2012-2022)
  1.4.7 The Midwest Triple-Negative Breast Cancer Treatment Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Triple-Negative Breast Cancer Treatment (2012-2022)
  1.5.1 United States Triple-Negative Breast Cancer Treatment Sales and Growth Rate (2012-2022)
  1.5.2 United States Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2012-2022)

2 UNITED STATES TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Triple-Negative Breast Cancer Treatment Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Triple-Negative Breast Cancer Treatment Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Triple-Negative Breast Cancer Treatment Average Price by Players/Suppliers (2012-2017)
2.4 United States Triple-Negative Breast Cancer Treatment Market Competitive Situation and Trends
  2.4.1 United States Triple-Negative Breast Cancer Treatment Market Concentration Rate
  2.4.2 United States Triple-Negative Breast Cancer Treatment Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Triple-Negative Breast Cancer Treatment Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES TRIPLE-NEGATIVE BREAST CANCER TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Triple-Negative Breast Cancer Treatment Sales and Market Share by Region (2012-2017)
3.2 United States Triple-Negative Breast Cancer Treatment Revenue and Market Share by Region (2012-2017)
3.3 United States Triple-Negative Breast Cancer Treatment Price by Region (2012-2017)

4 UNITED STATES TRIPLE-NEGATIVE BREAST CANCER TREATMENT SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Triple-Negative Breast Cancer Treatment Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Triple-Negative Breast Cancer Treatment Revenue and Market Share by Type (2012-2017)
4.3 United States Triple-Negative Breast Cancer Treatment Price by Type (2012-2017)
4.4 United States Triple-Negative Breast Cancer Treatment Sales Growth Rate by Type (2012-2017)

5 UNITED STATES TRIPLE-NEGATIVE BREAST CANCER TREATMENT SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Triple-Negative Breast Cancer Treatment Sales and Market Share by Application (2012-2017)
5.2 United States Triple-Negative Breast Cancer Treatment Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES TRIPLE-NEGATIVE BREAST CANCER TREATMENT PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Celgene
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Triple-Negative Breast Cancer Treatment Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Celgene Triple-Negative Breast Cancer Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Roche
  6.2.2 Triple-Negative Breast Cancer Treatment Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Roche Triple-Negative Breast Cancer Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Immunomedics GmbH
  6.3.2 Triple-Negative Breast Cancer Treatment Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Immunomedics GmbH Triple-Negative Breast Cancer Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Merck & Co., Inc.
  6.4.2 Triple-Negative Breast Cancer Treatment Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 F. Hoffmann-La Roche Ltd
  6.5.2 Triple-Negative Breast Cancer Treatment Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Eisai Co., Ltd
  6.6.2 Triple-Negative Breast Cancer Treatment Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview

7 TRIPLE-NEGATIVE BREAST CANCER TREATMENT MANUFACTURING COST ANALYSIS

7.1 Triple-Negative Breast Cancer Treatment Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Triple-Negative Breast Cancer Treatment

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Triple-Negative Breast Cancer Treatment Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Triple-Negative Breast Cancer Treatment Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Triple-Negative Breast Cancer Treatment Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Triple-Negative Breast Cancer Treatment Sales Volume Forecast by Type (2017-2022)
11.3 United States Triple-Negative Breast Cancer Treatment Sales Volume Forecast by Application (2017-2022)
11.4 United States Triple-Negative Breast Cancer Treatment Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Triple-Negative Breast Cancer Treatment
Figure United States Triple-Negative Breast Cancer Treatment Market Size (K Pcs) by Type (2012-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume Market Share by Type (Product Category) in 2016
Figure Alkylating Agents Product Picture
Figure Plant Products Product Picture
Figure Microorganism Products Product Picture
Figure Antimetabolites Product Picture
Figure Microtubule Stablizing Agents Product Picture
Figure United States Triple-Negative Breast Cancer Treatment Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Triple-Negative Breast Cancer Treatment by Application in 2016
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure United States Triple-Negative Breast Cancer Treatment Market Size (Million USD) by Region (2012-2022)
Figure The West Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Triple-Negative Breast Cancer Treatment Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Triple-Negative Breast Cancer Treatment Sales Share by Players/Suppliers
Figure 2017 United States Triple-Negative Breast Cancer Treatment Sales Share by Players/Suppliers
Figure United States Triple-Negative Breast Cancer Treatment Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Triple-Negative Breast Cancer Treatment Revenue Share by Players/Suppliers
Figure 2017 United States Triple-Negative Breast Cancer Treatment Revenue Share by Players/Suppliers
Table United States Market Triple-Negative Breast Cancer Treatment Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Triple-Negative Breast Cancer Treatment Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Triple-Negative Breast Cancer Treatment Market Share of Top 3 Players/Suppliers
Figure United States Triple-Negative Breast Cancer Treatment Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Triple-Negative Breast Cancer Treatment Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Triple-Negative Breast Cancer Treatment Product Category
Table United States Triple-Negative Breast Cancer Treatment Sales (K Pcs) by Region (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Sales Share by Region (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Share by Region (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Market Share by Region in 2016
Table United States Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Revenue Share by Region (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Revenue Market Share by Region (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Revenue Market Share by Region in 2016
Table United States Triple-Negative Breast Cancer Treatment Price (USD/Pcs) by Region (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Sales (K Pcs) by Type (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Sales Share by Type (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Share by Type (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Market Share by Type in 2016
Table United States Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Triple-Negative Breast Cancer Treatment by Type (2012-2017)
Figure Revenue Market Share of Triple-Negative Breast Cancer Treatment by Type in 2016
Table United States Triple-Negative Breast Cancer Treatment Price (USD/Pcs) by Types (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Growth Rate by Type (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Sales (K Pcs) by Application (2012-2017)
Table United States Triple-Negative Breast Cancer Treatment Sales Market Share by Application (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Market Share by Application (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Market Share by Application in 2016
Table United States Triple-Negative Breast Cancer Treatment Sales Growth Rate by Application (2012-2017)
Figure United States Triple-Negative Breast Cancer Treatment Sales Growth Rate by Application (2012-2017)
Table Celgene Basic Information List
Table Celgene Triple-Negative Breast Cancer Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Celgene Triple-Negative Breast Cancer Treatment Sales Growth Rate (2012-2017)
Figure Celgene Triple-Negative Breast Cancer Treatment Sales Market Share in United States (2012-2017)
Figure Celgene Triple-Negative Breast Cancer Treatment Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Triple-Negative Breast Cancer Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Roche Triple-Negative Breast Cancer Treatment Sales Growth Rate (2012-2017)
Figure Roche Triple-Negative Breast Cancer Treatment Sales Market Share in United States (2012-2017)
Figure Roche Triple-Negative Breast Cancer Treatment Revenue Market Share in United States (2012-2017)
Table Immunomedics GmbH Basic Information List
Table Immunomedics GmbH Triple-Negative Breast Cancer Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Immunomedics GmbH Triple-Negative Breast Cancer Treatment Sales Growth Rate (2012-2017)
Figure Immunomedics GmbH Triple-Negative Breast Cancer Treatment Sales Market Share in United States (2012-2017)
Figure Immunomedics GmbH Triple-Negative Breast Cancer Treatment Revenue Market Share in United States (2012-2017)
Table Merck & Co., Inc. Basic Information List
Table Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Sales Growth Rate (2012-2017)
Figure Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Sales Market Share in United States (2012-2017)
Figure Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Revenue Market Share in United States (2012-2017)
Table F. Hoffmann-La Roche Ltd Basic Information List
Table F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Sales Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Sales Market Share in United States (2012-2017)
Figure F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Revenue Market Share in United States (2012-2017)
Table Eisai Co., Ltd Basic Information List
Table Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Sales Growth Rate (2012-2017)
Figure Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Sales Market Share in United States (2012-2017)
Figure Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Triple-Negative Breast Cancer Treatment
Figure Manufacturing Process Analysis of Triple-Negative Breast Cancer Treatment
Figure Triple-Negative Breast Cancer Treatment Industrial Chain Analysis
Table Raw Materials Sources of Triple-Negative Breast Cancer Treatment Major Players/Suppliers in 2016
Table Major Buyers of Triple-Negative Breast Cancer Treatment
Table Distributors/Traders List
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Triple-Negative Breast Cancer Treatment Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Triple-Negative Breast Cancer Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Triple-Negative Breast Cancer Treatment Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources